Table 4

Transfusion requirements during the 48 hours after the first dose of trial drug in the placebo and rFVIIa groups

Placebo group
 rFVIIa group



n
 Median (range)
 n
 Median (range)
 Differences in medians
 Estimated reduction: median of differences (95% CI)a
 P valueb
RBC (units)






     All patients
 76
 6.5 (0–41)
 60
 4.4 (0–39.9)
 2.1
 2.6 (0.1; 5.1)
 0.02
     Alive at 48 hours
 65
 6.6 (0–41)
 48
 2.9 (0–20)
 3.7
 3.5 (1.7; 5.7)
 <0.001
FFP (ml)






     All patients
 60
 1,360 (0–6,912)
 42
 705 (0–9,000)
 655
 600 (0.00; 1,320)
 0.04
     Alive at 48 hours
 54
 1,400 (0–6,912)
 35
 660 (0–9,000)
 740
 800 (250.0; 1,420)
 0.001
Platelets (ml)






     All patients
 72
 300 (0–1,500)
 55
 147 (0–1,200)
 153
 50 (0; 250)
 0.09
     Alive at 48 hours
 62
 300 (0–1,500)
 46
 100 (0–900)
 200
 50 (0; 250)
 0.01

aThe Hodges-Lehman shift with 95% CI. Patients who died within 48 hours were assigned the highest rank for the Wilcoxon-Mann-Whitney test and the Hodges-Lehman estimate. bTwo-sided Wilcoxon-Mann-Whitney rank sum test. CI, confidence interval; FFP, fresh frozen plasma; RBC, red blood cell; rFVIIa, recombinant activated factor VII.

Rizoli et al. Critical Care 2006 10:R178   doi:10.1186/cc5133